Royalty Pharma plc (RPRX)
Health Care ยท Pharmaceutical Preparations
Royalty Pharma plc (RPRX) is listed on Nasdaq, where its shares have traded since June 16, 2020. SentiSense covers Royalty Pharma plc in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Pablo Legorreta is its chief executive officer. The company reports 100 employees, and its corporate website is www.royaltypharma.com.
About Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Latest reported results
Royalty Pharma plc reported revenue of $674.1 million for Q2 FY2026, up 16.5% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 633 institutions reported holding RPRX, with 362.5 million shares worth $20.3 billion in aggregate. The largest reported holders were Capital Group, Morgan Stanley and BlackRock. Of the 5 largest reported holders, 3 added shares and 2 reduced their positions during the quarter.
More on RPRX
- RPRX sentiment: whether news and social coverage of Royalty Pharma plc leans bullish or bearish, and the stories driving it.
- RPRX ownership: all 633 reporting institutions, plus insider and congressional trades.
- RPRX financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for Royalty Pharma plc: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Royalty Pharma plc do?
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products.
What sector is RPRX in?
SentiSense classifies Royalty Pharma plc in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does RPRX stock trade?
Royalty Pharma plc (RPRX) is listed on Nasdaq, where its shares have traded since June 16, 2020.
Who is the CEO of Royalty Pharma plc?
Pablo Legorreta is the chief executive officer of Royalty Pharma plc.